<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Sporadic inclusion body myositis: Counts of different types of abnormal fibers</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Wiley</publisher>
				<availability status="unknown"><p>Copyright Wiley</p>
				</availability>
				<date type="published" when="1996-01">1996-01</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">Ned</forename><surname>Pruitt</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Carol</forename><forename type="middle">J</forename><surname>Showalter</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andrew</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurolop</orgName>
								<orgName type="laboratory">Neurcimusc~ilar Research Laboratory</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochesrer</settlement>
									<region>MN</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">to I)r Engel. Department of Neurology</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Sporadic inclusion body myositis: Counts of different types of abnormal fibers</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Annals of Neurology</title>
						<title level="j" type="abbrev">Ann Neurol.</title>
						<idno type="ISSN">0364-5134</idno>
						<idno type="eISSN">1531-8249</idno>
						<imprint>
							<publisher>Wiley</publisher>
							<biblScope unit="volume">39</biblScope>
							<biblScope unit="issue">1</biblScope>
							<biblScope unit="page" from="139" to="143"/>
							<date type="published" when="1996-01" />
						</imprint>
					</monogr>
					<idno type="MD5">CE23C560E965421A71CD305A44E8BC05</idno>
					<idno type="DOI">10.1002/ana.410390122</idno>
					<note type="submission">Received jul 18. 1995, m d in revised h i n Aug 24. Accepted for publication Aug 24, 1995.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>a double-blind, placebo-conrrolled srudy. Neurology 1994;44:429-432</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>References 1. IOnsella CJ, Lange DJ, Trojaborg W, et al. The clinical and rlecrrophysiological correlares of elevated anri-GM, antibody titers. Ne~irology 1994;44:1278-I282 2. Santoro M, Thomas FP, Fink ME, er al. 1gM deposits at nodes of Ranvier i n a patient wirh miyorrophic lateral sclerosis, anri-G M , antibodies, and mulrifocal motor conduction block. A n n</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>imrnunoglobulin in the rremnenr of spontaneously acq~iired factor V1II:C Inhibitors. Am J Med 1991;91(suppl 5A):35S-39s 8. Thomas Fl', Lee AM, Ronias SN, Latov N. Monoclonal lgMs with anti-Gal(p1-3) GalNac activity in lower nioror neuron disease; identilicarion of glycoprotein anrigens in neural tissue and cross-reacriviry with serum immunoglobulins. J Neuroimniunol 1 %9;23: 167-174 9. Turner MW, Bennich HH. Nanig JB. Pepsin digestion of hunian Ginyeloma proteins of differenr subclasses. The characrerictic features of pepsin cleavage  The relative frequencies and significance of these features in the pathogenesis of sporadic IBM is still uncertain. The disease could be initiated or perpetuated by focal cytoplasmic or nuclear degradation, accumulation of amyloid related proteins, an autoimmune attack on the muscle fibers by T cells, by a combination of any of these factors, or by a yet unidentified mechanism. One may speculate that muscle fiber destruction may result from nuclear damage, the accumulation of amyloid-related proteins, invasion of fibers by autoaggressive inflammatory cells, or necrosis. In this study, we assess the relative frequencies of congophilic amyloid deposits, invasion of nonnecrotic fibers by T cells, and fiber necrosis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subjects and Methods</head><p>Thirty-one consecutive and electron microscopy proven cases of sporadic IBM were studied. Twenty-eight patients were male and 3 were female. Twenty were untreated or had received no treatment for at least 3 months prior to biopsy (Table <ref type="table">1</ref>). Eleven had received prednisone, sometimes in combination with azathioprine, methotrexate, or cyclosporin A (Table <ref type="table" target="#tab_2">2</ref>). All 11 showed progression of weakness despite therapy, consistent with the notable refractoriness of IBM to therapy [2, 31. The mean ages at biopsy and duration of symptoms before biopsy were not significantly different. The mean duration of prednisone treatment was 68.4 months. The mean dose of prednisone was 247 mglweek.</p><p>Two consecutive 1 0-pm cryostat sections were analyzed in each case. One section was stained with Congo red <ref type="bibr" target="#b2">[6]</ref> Table <ref type="table">I</ref>    and examined under rhodamine fluorescence optics <ref type="bibr" target="#b5">[9]</ref> to detect the congophilic deposits in rhe fibers (Fig 1E </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results and Discussion</head><p>There was a wide dispersion in the frequency of the different species of abnormal fibers in the sampled population. For all 31 patients, however, the frequency of invaded fibers (mean, 24.31 1,000; median, 19.7/ 1.000) was severalfold higher than that of the CR+ fibers (mean, 3.1 / 1,000; median, 3.1 / 1,000) or that of the necrotic fibers ( ~~i ~i i i , 3.1 / 1,000; median, 2.1 / 1,000).</p><p>The results for the 20 untreated and 11 treated patients are shown separately in Tables 1 and 2 and in Figure <ref type="figure" target="#fig_1">2</ref>. The following can be nored: (1) In all patients except Patient 21, the invaded fibers were more frequent than the CR+ fibers. T h e mean and median frequencies of the invaded fibers were severalfold higher than the corresponding frequencies of the C R + fibers in either the untreated or treated group ( p &lt; 0.001 for the untreated and p &lt; 0.05 for the treated group).</p><p>(2) The frequencies of invaded fibers in the treated and untreated groups were not significantly different. (3) In a similar manner, the frequencies of the CR+ fibers in the treated and untreated groups were not significantly different. (4) The frequencies of necrotic fibers i n the treated and untreated groups were not significantly different. <ref type="bibr" target="#b0">( 5 )</ref> There was no significant correlation between the frequency of invaded fibers and syniptom duration in either group. <ref type="bibr" target="#b2">(6)</ref> There was no significant correlation between the frequency of C R + fibers and symptom duration in either group. <ref type="bibr" target="#b3">(7)</ref> There was no significant correlacion between the frequency of invaded fibers and length of treatment in the treated group. <ref type="bibr" target="#b4">(8)</ref> There was no significant correlation benveen the frequency of CR+ fibers and length of treatment in the treated group. <ref type="bibr" target="#b5">(9)</ref> There was no significant correlation between Congo red positivity and muscle fiber invasion or necrosis.</p><p>We also determined the frequencies of fibers that were both necrotic and C R + , or both invaded and CR+. These frequencies were generally less than 0.5/ 1,000 and the corresponding values for the treated and untreated parients were not significantly different. This indicates that the CR+ fibers are neither exempt from nor selectively vulnerable to necrosis or cell-mediated cytotoxicity .</p><p>The much higher frequency of invaded fibers than of CR+ fibers suggests that in sporadic IBM, T cell-mediated niyocytotoxicity has greater pathologic significance than the accumulation of congophilic deposits and points to the importance of an immunemediated mechanism in the disease. O n the other hand, the congophilic deposits may only be the end result of focal cytoplasmic or nuclear degeneration that were not assessed in the present study.</p><p>The frequencies of the observed abnormalities were not significantly different in treated and untreated patients. This comparison might have been more precise if the same patients had been biopsied before and after treatment; but even then a sampling error t~iay arise due to the focality of the pathologic process. In this connection, two recent studies of patients biopsied before and after prednisone therapy are of interest. O n e study of 8 patients found a decreased number of T cell-invaded fibers after treatment for a mean period of 13.6 months [ 131. The other study found no change in the number of inflammatoiy infiltrates after 3 months of therapy <ref type="bibr" target="#b10">[14]</ref>. Neither study states the frequency of invaded fibers before or after therapy. Our findings indicate that (1) after long-term (mean: 68.4 months) prednisone treatment T cell-mediated myocytotoxicity remained the most frequrnt pathologic alteration in 10 of 1 1 patients, and (2) neither longterm treatment nor prolonged disease duration were associated with a significant change in the median frequency of any species of abnormal fibers. These findings point away from the notion that sporadic IBM is a degenerative disease conditioned by progressive accumulation of arnyloid deposits in the muscle fibers. O n the other hand, the results do not establish T cell-mediated myocytoxicity as the main pathogenic event in sporadic IBM. Finally, our observations shed no light on the factors that initiate the various pathologic reactions or how the various reactions are interrelated or perpetuated in the course of the disease.</p><p>This study was supported by N I H grants NS6277 (A.G.E) and HD7447 (C.J.S) and by a research grant from the Muscular Dystrophy Association (A.G.E).</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>fig 1 .</head><label>1</label><figDesc>fig 1. Muscle Jibers surrounded and invaded by mononuclear cells (A-0) or harboring congophilic inclusions (E). The invading mononuclear cells occupy supeficial (A) or deep (B-0) regions of the fibers. Fiber imaged in C is nearly completely destroyed by the invading cells. Panels (A-0) are JFom inclusion body myositis putients treated for 3 years or longer with prednisone. Panel E is JFom an untreated patient. Dark granules in panel B (x) are due to arti$ct. (A-C) Trichrome stain. (0) Immunostain for the CD3 T-cell marker, juorescence optics. (E) Congo red stain, juoresrence optics. (A-C, X 330; D and E, X 360.)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig 2 .</head><label>2</label><figDesc>Fig 2. Freqtieniiex ?f Corigo red-positive, T cell-inuaded, m d necrotic jberj in mtreated a i d trtzted inr.lrtsion body ? y o -&gt;-itis.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Invasion of nonnecrotic muscle fibers by cytotoxic T cells, accumulation of congophilic amyloid inclusions in mus- cle fibers, and fiber necrosis are consistent histologic findings in sporadic inclusion body myositis (IBM). To evaluate the relative significance of these alterations, we quantitatively analyzed the frequency of these abnormali- ties in 31 electron microscopy proven cases of IBM (20 untreated and 11 immunosuppressed). Nonnecrotic mus- cle fibers invaded by T cells were severalfold more fre- quent than fibers displaying the other pathologic alter- ations. Comparison of muscle samples from treated and untreated patients revealed no significant differences in the respective frequencies of the three species of abnormal fibers. Moreover, there was no correlation of the fre- quency of any abnormality either with disease duration or length of treatment. The much higher Frequency of the invaded than Congo red-positive fibers points to the importance of an immune-mediated mechanism in the disease; but the basic cause of the disease remains unde- fined.</head><label></label><figDesc>as ; 1 function of time. Clin</figDesc><table><row><cell></cell><cell>Sooradic Inclusion Bodv 1 d</cell></row><row><cell></cell><cell>Mvositis: Counts of Different Types of</cell></row><row><cell></cell><cell>Abnormal Fibers</cell></row><row><cell></cell><cell>J. Ned Pruitt 11, MD, Carol J. Showalter, MD. and</cell></row><row><cell></cell><cell>Andrew G. Engel, MD</cell></row><row><cell></cell><cell>Pruitt J N 11, Showalter CJ, Engel AG. Sporadic</cell></row><row><cell></cell><cell>inclusion body myositis: counts of differenr types</cell></row><row><cell></cell><cell>of abnormal fibers. Ann Neurol 1996;39:1.39-143</cell></row><row><cell></cell><cell>Sporadic inclusion body myositis (IBM) has been rec-</cell></row><row><cell></cell><cell>ognized as a disease entity since 1971 [ I ] . The clinical</cell></row><row><cell></cell><cell>[2-41 as well as histopathological [l-3, 5-81 features</cell></row><row><cell></cell><cell>of the disease distinguish it from other inflammatory</cell></row><row><cell></cell><cell>myopathies, but its pathogenesis remains obscure. De-</cell></row><row><cell></cell><cell>fining characteristics at the light microscopy level in-</cell></row><row><cell></cell><cell>clude rimmed vacuoles, congophilic amyloid deposits</cell></row><row><cell>Enp Immunol 1970;7:603-625 10. Noya FJ, Rench IMA, Courtney JT, er al. Pharniacokinrtics of intravenous immunoglobulin in vei? low birth weight neo-</cell><cell>(Fig 1E) typically near or within the vacuoles and occa-sionally in nuclei, invasion of nonnecrotic muscle fibers by autoaggressive T cells and macrophages (Fig</cell></row><row><cell>nates. Prdiatr Infect Dis J 1989;8:759-763</cell><cell>1 A-D), necrotic and regenerating fibers, small groups</cell></row><row><cell>1 1. Latov N. Antibodies ro glycoconjugarrs in neurologic disease.</cell><cell>of atrophic fibers, and mitochondria1 abnormalities.</cell></row><row><cell>Clin Aspects Autoimmun 1990;4: 18-29</cell><cell></cell></row><row><cell>12. Rossi F, Dierrich G, Kazatchkine MD. Anri-idiotypes againat</cell><cell></cell></row><row><cell>autoantibodies in normal immunoglobulins: evidence for net-</cell><cell></cell></row><row><cell>work regulation of human autoimmune responses. Immunol</cell><cell></cell></row><row><cell>Rev 1989:ll 0:135-149</cell><cell></cell></row><row><cell>13. Tankersley DL. Dimer forination in imrnunogloliuli~~ prepara-</cell><cell></cell></row></table><note>tiims and speculations on rhe mechanism of acrion of inrraven o w immune globulin in autoimmune diseases. Inimunol Rev 1904;139:159-172 14. Axford JS, Sumar N. Alavi A, er al. Changes i n normal glycosylarion mechanisms in autoimmune rheilmaric disease. J Clin Invest 1992;89:1O21-103 I</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc>. IBM: Untreated Patients</figDesc><table><row><cell></cell><cell></cell><cell>Symptom</cell><cell></cell><cell>I nvadcd</cell><cell>Necrotic</cell></row><row><cell></cell><cell></cell><cell>Duration</cell><cell>CR+ fibers</cell><cell>Fibers</cell><cell>Fibers</cell></row><row><cell>Patient No.</cell><cell>Age (yr), Sex</cell><cell>(yr)</cell><cell>(no./l,OOO)</cell><cell>(110./1,000)</cell><cell>(no./1,000)</cell></row><row><cell>1</cell><cell>62, M</cell><cell>2</cell><cell>1.9</cell><cell>40.3</cell><cell>I .7</cell></row><row><cell>2</cell><cell>67, M</cell><cell>5</cell><cell>5.5</cell><cell>19.7</cell><cell>5.5</cell></row><row><cell>3</cell><cell>79, M</cell><cell>15</cell><cell>3.5</cell><cell>62.9</cell><cell>7.4</cell></row><row><cell>4</cell><cell>69, M</cell><cell>2</cell><cell>1.4</cell><cell>26.7</cell><cell>2.2</cell></row><row><cell>5</cell><cell>69, M</cell><cell>8</cell><cell>4.5</cell><cell>21.2</cell><cell>0.7</cell></row><row><cell>6</cell><cell>62, M</cell><cell>5</cell><cell>2.8</cell><cell>53.4</cell><cell>6.6</cell></row><row><cell>7</cell><cell>67, M</cell><cell>8</cell><cell>5.0</cell><cell>72.8</cell><cell>1.7</cell></row><row><cell>8</cell><cell>73, M</cell><cell>0.5</cell><cell>3.6</cell><cell>25.8</cell><cell>4.2</cell></row><row><cell>9</cell><cell>58, M</cell><cell>2</cell><cell>4.5</cell><cell>7.8</cell><cell>9.1</cell></row><row><cell>10</cell><cell>55, M</cell><cell>8</cell><cell>1.7</cell><cell>19.1</cell><cell>0.6</cell></row><row><cell>1 1</cell><cell>7 2 , M</cell><cell>3</cell><cell>1.3</cell><cell>34.4</cell><cell>3. I</cell></row><row><cell>12</cell><cell>60, F</cell><cell>5</cell><cell>0.8</cell><cell>44.6</cell><cell>3.9</cell></row><row><cell>13</cell><cell>81, M</cell><cell>5</cell><cell>4.4</cell><cell>22.6</cell><cell>0.8</cell></row><row><cell>14</cell><cell>60, M</cell><cell>6</cell><cell>1.7</cell><cell>4.0</cell><cell>2.6</cell></row><row><cell>15</cell><cell>84, M</cell><cell>6</cell><cell>0.5</cell><cell>4.0</cell><cell>0.2</cell></row><row><cell>16</cell><cell>43, M</cell><cell>5</cell><cell>3.8</cell><cell>3.8</cell><cell>0.8</cell></row><row><cell>17</cell><cell>71, F</cell><cell>12</cell><cell>1.1</cell><cell>24.0</cell><cell>1.6</cell></row><row><cell>18</cell><cell>45, M</cell><cell>1.5</cell><cell>3.6</cell><cell>11.1</cell><cell>1.3</cell></row><row><cell>19</cell><cell>61, M</cell><cell>4</cell><cell>0.9</cell><cell>3.0</cell><cell>2.1</cell></row><row><cell>20</cell><cell>65, M</cell><cell>10</cell><cell>2.9</cell><cell>11.8</cell><cell>3.4</cell></row><row><cell>Mean f SE</cell><cell>65.2 2 2.3</cell><cell>5.6 f 0.8</cell><cell>2.7 ? 0.35</cell><cell>25.6 % 4.5</cell><cell>3.0 % 0.6</cell></row><row><cell>Median</cell><cell>64</cell><cell>5</cell><cell>2.9</cell><cell>21.9</cell><cell>2.1</cell></row><row><cell>~~~</cell><cell>~</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IBM</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note>= Inclusion body rnyositis; CR+ = Congo red-positive.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc>IBM: Treated Patients</figDesc><table><row><cell></cell><cell></cell><cell>Symptom</cell><cell></cell><cell>Treatment</cell><cell></cell><cell>CR+</cell><cell>Invaded</cell><cell>Necrotic</cell></row><row><cell></cell><cell cols="2">Age (yr), Duration</cell><cell cols="2">Prednisone Duration</cell><cell>Other</cell><cell>Fibers</cell><cell>Fibers</cell><cell>Fibers</cell></row><row><cell>Patient No.</cell><cell>Sex</cell><cell>(Yd</cell><cell>(mg/week)</cell><cell>(nio)</cell><cell>Treatment</cell><cell cols="3">(no./1,000) (no./1,000) (no./1,000)</cell></row><row><cell>21</cell><cell>71. M</cell><cell>5</cell><cell>140</cell><cell>60</cell><cell></cell><cell>4.2</cell><cell>1 .o</cell><cell>1.4</cell></row><row><cell>22</cell><cell>57, M</cell><cell>11</cell><cell>385</cell><cell>120</cell><cell>Am, 7 2 mo</cell><cell>0.2</cell><cell>1.2</cell><cell>0.4</cell></row><row><cell>23</cell><cell>50. M</cell><cell>7</cell><cell>105</cell><cell>84</cell><cell cols="2">MTX. 5 mo 3.1</cell><cell>17.1</cell><cell>0.4</cell></row><row><cell>24</cell><cell>61, M</cell><cell>3</cell><cell>210</cell><cell>12</cell><cell></cell><cell>2.3</cell><cell>57.9</cell><cell>3.2</cell></row><row><cell>25</cell><cell>7 0 , F</cell><cell>8</cell><cell>140</cell><cell>88</cell><cell>Aza, 7 2 mo</cell><cell>8.2</cell><cell>12.3</cell><cell>2.6</cell></row><row><cell>26</cell><cell>51, M</cell><cell>7</cell><cell>88</cell><cell>84</cell><cell>Aza. 36 mo</cell><cell>4.3</cell><cell>39.1</cell><cell>6.4</cell></row><row><cell>27</cell><cell>47, M</cell><cell>20</cell><cell>175</cell><cell>240</cell><cell cols="2">h a , 132 nio 2.9</cell><cell>3.9</cell><cell>11.7</cell></row><row><cell>28</cell><cell>62, M</cell><cell>3</cell><cell>70</cell><cell>22</cell><cell>CSA, 9 [no</cell><cell>4.3</cell><cell>6.2</cell><cell>1 .o</cell></row><row><cell>29</cell><cell>68, M</cell><cell>5</cell><cell>420</cell><cell>9</cell><cell></cell><cell>2.1</cell><cell>46.6</cell><cell>1.6</cell></row><row><cell>30</cell><cell>63, M</cell><cell>4</cell><cell>560</cell><cell>34</cell><cell></cell><cell>4.6</cell><cell>45.4</cell><cell>7.9</cell></row><row><cell>31</cell><cell>60, M</cell><cell>2</cell><cell>420</cell><cell>2</cell><cell></cell><cell>5.2</cell><cell>7.6</cell><cell>1 .o</cell></row><row><cell cols="2">Mean 2 SE 60 IT 2.4</cell><cell cols="2">6.8 f 1.5 247 ? 51</cell><cell>68.4 ? 20.8</cell><cell></cell><cell>3.8 f 0.6</cell><cell>21.7 ? 6.4</cell><cell>3.4 2 1.1</cell></row><row><cell>Median</cell><cell>61</cell><cell>5</cell><cell>175</cell><cell>60</cell><cell></cell><cell>4.2</cell><cell>12.3</cell><cell>1.6</cell></row></table><note>1BM = Inclusion body myositis: CR+ = Congo red-positive; h a = az'irhioprine; M T X = rnethotrexare; CSA 2 cyrlosporin A. Brief Communication: Pruitt et al: Sporadic IBM: Counts of Abnormal Fibers 141 15318249, 1996, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/ana.410390122 by University Of Illinois At Urbana Champaign, Wiley Online Library on [07/03/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head></head><label></label><figDesc>). 7'he section was then stained with trichrorne and the invaded fibers (Fig 1A-D) and necrotic fihers were identified by conventional criteria[lo]. In the second section, the CD3 Tcell marker was irnmunolocalized to visualize muscle fibers invaded by T cells [ 111. The frequencies of invaded fibers detected by the two methods were nor significantly different by the paired t-test. To avoid any selection bias, all muscle fibers in all sections were photographed and counted [ 121. A total of 114,797 muscle fibers, or 311 average of 3,700 fibers per biopsy, were surveyed. All Congo red-positive (CRt), all necrotic, and all invaded fibers were counted in each section. The results were analyzed using the Mann-Whitney rank sum rest a n d the Spearman rank corre-</figDesc><table /><note>lation test.</note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="15318249" xml:id="foot_0">, 1996, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/ana.410390122 by University Of Illinois At Urbana Champaign, Wiley Online Library on [07/03/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</note>
		</body>
		<back>

			<div type="funding">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Supporred in parr by the Albert Einsrein Cancer Cenrer Core Grant P3OCA 13330-21 awarded by the National Cancer Insrirure and by center grants from rhe Muscular Dysrrophy Associarion and N l H (NINCS NSI 1766) to the Deparrment of Neurology, Columhia University. Dr Oleksowicz is a recipienr of an American Cancer Society Clinical Oncology Career Development Award (CDA 9.3-52).</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Inclusion body myosiris: a distinct variety of idiopathic inflammatory myopathy</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Yunis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Samaha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Carpenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Heller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A ;</forename><surname>Eisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">P</forename><surname>Lotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nishino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lab Invest</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="727" to="747" />
			<date type="published" when="1971">1971. 1978. 1989</date>
		</imprint>
	</monogr>
	<note>Brain</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Monoclonal antibody analysis of mononuclear cells in myopathies. 1: Quantiration of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mikol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Arahata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<editor>Myology.</editor>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="133" to="208" />
			<date type="published" when="1984">1994. 1984</date>
			<publisher>McGraw-Hill</publisher>
		</imprint>
	</monogr>
	<note>Inclusion body myositis</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mendell</surname></persName>
		</author>
		<author>
			<persName><surname>Sahenk 2</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gales</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Paul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1229" to="1234" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Idiopathic inflammatory myopathies: inclusion body myosiris, polymyosiris, and dermatomyosiris</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mirabella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Neurol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="448" to="456" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Mitochondria1 DNA deletions in inclusion body myositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Oldfors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N-G</forename><surname>Larsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lindberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Holme</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Enhanced detection of Congo-red positive amyloid deposits in muscle fibers of inclusion body myosiris and brain of Alzheimer&apos;s disease using fluorescence technique</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="1265" to="1266" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">Basic reactions of muscle</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Q</forename><surname>Banker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<editor>Myology.</editor>
		<imprint>
			<date type="published" when="1994">1994</date>
			<publisher>McGraw-Hill</publisher>
			<biblScope unit="page" from="832" to="888" />
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
	<note>2nd ed</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Eosinophilia myalgia syndrome: I. Immunocyrochenlical evidence for a T-cell-mediated immune effector response</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Emslie-Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Uuffy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Bowles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Intracellular calcium accumularion in Duchenne dystrophy and other myopathies: a study of 567,000 muscle fibers in 114 biopsies</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Bodensteiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="439" to="446" />
			<date type="published" when="1978">1978</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Sahenk 2, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Barohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Amato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1302" to="1304" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Local T-cell proliferation and differentiation in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">C</forename><surname>Lindberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oldfors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tarkowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J lmmunol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="524" to="528" />
			<date type="published" when="1991">1995. 1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<idno type="DOI">10.1002/ana.410390122</idno>
		<idno>07/03/2023</idno>
		<ptr target="https://onlinelibrary.wiley.com/terms-and-conditions" />
		<title level="m">Pruitt et al: Sporadic IBM: C o u n t s of Abnormal Fibers 143 15318249</title>
				<meeting><address><addrLine>Urbana Champaign, Wiley Online Library</addrLine></address></meeting>
		<imprint>
			<publisher>on Wiley Online Library for rules of use</publisher>
			<date type="published" when="1996">1996</date>
			<biblScope unit="volume">1</biblScope>
		</imprint>
	</monogr>
	<note>See the Terms and Conditions. OA articles are governed by the applicable Creative Commons License</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
